Peter Probst
Overview
Explore the profile of Peter Probst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tarcha E, Olsen C, Probst P, Peckham D, Munoz-Elias E, Kruger J, et al.
PLoS One
. 2017 Jul;
12(7):e0180762.
PMID: 28723914
Background: Dalazatide is a specific inhibitor of the Kv1.3 potassium channel. The expression and function of Kv1.3 channels are required for the function of chronically activated memory T cells, which...
2.
Probst P, Grigg J, Wang M, Munoz E, Loo Y, Ireton R, et al.
Vaccine
. 2017 Mar;
35(15):1964-1971.
PMID: 28279563
Vaccine adjuvants are essential to drive a protective immune response in cases where vaccine antigens are weakly immunogenic, where vaccine antigen is limited, or where an increase in potency is...
3.
Gerges C, Gerges M, Lang M, Zhang Y, Jakowitsch J, Probst P, et al.
Chest
. 2013 Apr;
143(3):758-766.
PMID: 23580984
Background: Left-sided heart disease (LHD) is the most common cause of pulmonary hypertension (PH). In patients with LHD, elevated left atrial pressure causes a passive increase in pulmonary vascular pressure...
4.
Scalley-Kim M, Hess B, Kelly R, Krostag A, Lustig K, Marken J, et al.
PLoS One
. 2012 Aug;
7(8):e43332.
PMID: 22912856
Chemokines play a key role in leukocyte recruitment during inflammation and are implicated in the pathogenesis of a number of autoimmune diseases. As such, inhibiting chemokine signaling has been of...
5.
Humenberger M, Rosenhek R, Gabriel H, Rader F, Heger M, Klaar U, et al.
Eur Heart J
. 2010 Oct;
32(5):553-60.
PMID: 20943671
Aims: To evaluate the effect of age on the clinical benefit of atrial septal defect (ASD) closure in adults. Methods And Results: Functional status, the presence of arrhythmias, right ventricular...
6.
Bayard Y, Omran H, Neuzil P, Thuesen L, Pichler M, Rowland E, et al.
EuroIntervention
. 2010 Jun;
6(2):220-6.
PMID: 20562072
Aims: The European PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study was performed to determine the safety and efficacy of left atrial appendage occlusion by catheter technique. Embolic stroke due...
7.
Gyongyosi M, Christ G, Lang I, Kreiner G, Sochor H, Probst P, et al.
JACC Cardiovasc Interv
. 2009 Aug;
2(8):718-27.
PMID: 19695539
Objectives: The multicenter AUTAX (Austrian Multivessel TAXUS-Stent) registry investigated the 2-year clinical/angiographic outcomes of patients with multivessel coronary artery disease after implantation of TAXUS Express stents (Boston Scientific, Natick, Massachusetts),...
8.
Coler R, Bhatia A, Maisonneuve J, Probst P, Barth B, Ovendale P, et al.
FEMS Immunol Med Microbiol
. 2009 Mar;
55(2):258-70.
PMID: 19281568
Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection worldwide, with over 91 million cases estimated annually. An effective subunit vaccine against Chlamydia may require a multivalent subunit...
9.
Strehblow C, Gyongyosi M, Zenker G, Wallner H, Heigert M, Siostrzonek P, et al.
Coron Artery Dis
. 2007 May;
18(4):305-11.
PMID: 17496495
Background: In current clinical practice, 35-67% of significant coronary artery lesions are located in small (<3.0 mm) vessels, a setting with poor short- and long-term results after percutaneous coronary interventions....
10.
Alderson M, McGowan P, Baldridge J, Probst P
J Endotoxin Res
. 2006 Oct;
12(5):313-9.
PMID: 17059695
Monophosphoryl lipid A (MPL) is a potent vaccine adjuvant derived from Salmonella minnesota that was recently licensed in Europe as a component of an improved vaccine for hepatitis B (Fendrix)....